Publicaciones en las que colabora con XERARDO XUSTO GARCIA MERA (24)

2024

  1. Exploring Biginelli-based scaffolds as A2B adenosine receptor antagonists: Unveiling novel structure-activity relationship trends, lead compounds, and potent colorectal anticancer agents

    Biomedicine and Pharmacotherapy, Vol. 173

2023

  1. Exploring the Effect of Halogenation in a Series of Potent and Selective A2BAdenosine Receptor Antagonists

    Journal of Medicinal Chemistry, Vol. 66, Núm. 1, pp. 890-912

  2. Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs

    Biomedicine and Pharmacotherapy, Vol. 164

  3. Stapling Amantadine to Melanostatin Neuropeptide: Discovery of Potent Positive Allosteric Modulators of the D2 Receptors

    ACS Medicinal Chemistry Letters, Vol. 14, Núm. 12, pp. 1656-1663

2022

  1. A 2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 5

  2. Exploring Non-orthosteric Interactions with a Series of Potent and Selective A3Antagonists

    ACS Medicinal Chemistry Letters, Vol. 13, Núm. 2, pp. 243-249

  3. Optimization of 2-Amino-4,6-diarylpyrimidine-5-carbonitriles as Potent and Selective A1Antagonists

    Journal of Medicinal Chemistry, Vol. 65, Núm. 3, pp. 2091-2106

2021

  1. 3,4-Dihydropyrimidin-2(1H)-ones as Antagonists of the Human A2B Adenosine Receptor: Optimization, Structure-Activity Relationship Studies, and Enantiospecific Recognition

    Journal of medicinal chemistry, Vol. 64, Núm. 1, pp. 458-480

  2. Discovery of New Potent Positive Allosteric Modulators of Dopamine D2Receptors: Insights into the Bioisosteric Replacement of Proline to 3-Furoic Acid in the Melanostatin Neuropeptide

    Journal of Medicinal Chemistry, Vol. 64, Núm. 9, pp. 6209-6220

2020

  1. Nitrogen-Walk Approach to Explore Bioisosteric Replacements in a Series of Potent A2B Adenosine Receptor Antagonists

    Journal of medicinal chemistry, Vol. 63, Núm. 14, pp. 7721-7739

2019

  1. Synthesis, Pharmacological, and Biological Evaluation of MIF-1 Picolinoyl Peptidomimetics as Positive Allosteric Modulators of D2R

    ACS Chemical Neuroscience, Vol. 10, Núm. 8, pp. 3690-3702

  2. Trifluorinated Pyrimidine-Based A2B Antagonists: Optimization and Evidence of Stereospecific Recognition

    Journal of Medicinal Chemistry, Vol. 62, Núm. 20, pp. 9315-9330

2018

  1. Perturbation Theory/Machine Learning Model of ChEMBL Data for Dopamine Targets: Docking, Synthesis, and Assay of New l -Prolyl- l -leucyl-glycinamide Peptidomimetics

    ACS Chemical Neuroscience, Vol. 9, Núm. 11, pp. 2572-2587

2017

  1. Development of Fluorescent Probes that Target Serotonin 5-HT2B Receptors

    Scientific Reports, Vol. 7, Núm. 1

  2. Enantiospecific Recognition at the A2B Adenosine Receptor by Alkyl 2-Cyanoimino-4-substituted-6-methyl-1,2,3,4-tetrahydropyrimidine-5-carboxylates

    Journal of Medicinal Chemistry, Vol. 60, Núm. 8, pp. 3372-3382

2015

  1. Synthesis by microwave-assisted 1,3-dipolar cycloaddition of 1,2,3-triazole 1'-homo-3'-isoazanucleosides and evaluation of their anticancer activity

    European Journal of Medicinal Chemistry, Vol. 98, pp. 212-220

2013

  1. Discovery of 3,4-dihydropyrimidin-2(1 H)-ones as a novel class of potent and selective A2B adenosine receptor antagonists

    ACS Medicinal Chemistry Letters, Vol. 4, Núm. 11, pp. 1031-1036

  2. Selective and potent adenosine A3 receptor antagonists by methoxyaryl substitution on the N-(2,6-diarylpyrimidin-4-yl)acetamide scaffold

    European Journal of Medicinal Chemistry, Vol. 59, pp. 235-242

2011

  1. Pyrimidine derivatives as potent and selective A3 adenosine receptor antagonists

    Journal of Medicinal Chemistry, Vol. 54, Núm. 2, pp. 457-471

2010

  1. Synthesis and pharmacological evaluation of novel 1,3,8- and 1,3,7,8-substituted xanthines as adenosine receptor antagonists

    Bioorganic and Medicinal Chemistry, Vol. 18, Núm. 5, pp. 2001-2009